Cytosorbents Corp (NASDAQ:CTSO)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a research report issued on Thursday.

The analysts wrote, “Summary Cytosorbents highlights recent cases using CytoSorb to successfully treat HLH (hemophagocytic lymphohistiocytosis) and notes the relevance of these cases to cytokine release syndrome (CRS) in cancer immunotherapy patients. Cytosorbents has now treated 10 secondary HLH patients with CytoSorb, with 3 published case reports and others pending. This month in the Journal of Clinical Immunology, in a case report entitled, Rescue of Cytokine Storm Due to HLH by Hemoadsorption in a CTLA4-Deficient Patient”, Greil and colleagues report the use of CytoSorb in successfully treating a 50-year old man with secondary HLH due to Epstein Barr virus (EBV) infection and associated Hodgkin’s lymphoma, and complicated by CTLA-4 deficiency. CTLA-4 deficiency is a genetic disorder that eliminates a key regulatory control element of cellular immunity and predisposes patients to severe inflammation. This patient was initially admitted for recurrent fevers, and was subsequently found to have a high grade EBV infection that triggered HLH, with kidney failure (requiring dialysis), liver failure, respiratory failure (requiring mechanical ventilation), shock (requiring vasopressors), and high inflammatory cytokines and other biomarkers. Despite the use of conventional HLH therapy, including high dose steroids, etoposide, and rituximab due to EBV infection, the patient worsened with progressive multi-organ failure. At that time, treatment with CytoSorb was initiated, subsequently treating for 4 consecutive days, each day with a new cartridge.””

Several other research analysts have also weighed in on CTSO. B. Riley reissued a “buy” rating and set a $11.25 price objective on shares of Cytosorbents Corp in a research note on Saturday, March 11th. Aegis reissued a “buy” rating on shares of Cytosorbents Corp in a research note on Tuesday, March 7th. Finally, HC Wainwright lifted their price target on shares of Cytosorbents Corp from $11.50 to $13.00 and gave the company a “buy” rating in a research note on Monday, March 6th. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $15.65.

Analyst Recommendations for Cytosorbents Corp (NASDAQ:CTSO)

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.7009% during midday trading on Thursday, hitting $5.4001. 18,164 shares of the company were exchanged. The company’s market capitalization is $137.83 million. The company has a 50-day moving average of $5.51 and a 200 day moving average of $5.60. Cytosorbents Corp has a one year low of $3.87 and a one year high of $6.90.

Your IP Address:

A hedge fund recently raised its stake in Cytosorbents Corp stock. Advisor Group Inc. boosted its position in Cytosorbents Corp (NASDAQ:CTSO) by 1.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 305,145 shares of the company’s stock after buying an additional 3,300 shares during the period. Advisor Group Inc. owned about 1.20% of Cytosorbents Corp worth $1,953,000 as of its most recent SEC filing. 6.07% of the stock is currently owned by institutional investors.

About Cytosorbents Corp

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

5 Day Chart for NASDAQ:CTSO

Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.